Leaving no-one behind: A set of policy principles to meet the global challenge of Rare Diseases
Rare diseases pose unique challenges to patients, their families, society, healthcare professionals and healthcare systems.
Read more
Switching describes a physician’s decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs. The considerations take into account the unique characteristics of...
Read moreCosts of cancer drugs have risen significantly in Switzerland over the past ten years, from an estimated CHF 445 million to CHF 775 million at ex-factory prices. Bearing in mind future combination treatments in immune-oncology, treatments which are likely to bring from now on unhoped for outcomes, it is timely to reflect on new kinds...
Read moreThis new set of policy principles outlines critical elements for a global framework on rare disease policy.
Read moreRare diseases pose unique challenges to patients, their families, society, healthcare professionals and healthcare systems.
Read more
Rare diseases are a group of conditions which affect very small numbers of people. Definitions vary, although generally a disease is considered rare if it affects fewer than 1-5 individuals per 10,000 in the general population.
Read more
We need an informed societal debate on how much prolonging life should be allowed to cost (Note to our readers: This is a re-posting that was first published on Monday 27 February in the Basler Zeitung) Recently, the Secretary of Health for the Swiss canton of Zurich, Thomas Heiniger, called for a “fact-based societal debate” on...
Read moreIFPMA, the international association representing the innovative biopharmaceutical industry, welcomes the G-FINDER 2016[1] results, which shows that industry consolidated its status as a main funder of neglected disease R&D in 2015. These R&D efforts are a critical area where the research-based biopharmaceutical industry supports the global health community in putting an end to some of...
Read moreGeneva, 10 February 2017 – IFPMA has just published its 2017 facts & figures report containing a wealth of data and trends on biopharmaceutical innovation, global health, and the economic footprint of the industry. The Report provides an overview of our R&D pipeline, with 56 new medicinal products launched in 2015, more than 7,000 compounds...
Read moreToday the International Federation of Pharmaceutical Wholesalers (IFPW) begins its role as secretariat of Fight the Fakes, the global campaign to raise awareness of the threat fake medicines pose to people and public health. Launched in November 2013, Fight the Fakes has grown into a coalition of over 30 organizations, including healthcare professionals, academia, NGOs,...
Read more